Q2 2014 13F Holders as of 30 Jun 2014
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
123,650,000
-
Number of holders
-
127
-
Total 13F shares, excl. options
-
85,679,010
-
Shares change
-
-628,596
-
Total reported value, excl. options
-
$846,469,840
-
Value change
-
-$18,616,849
-
Put/Call ratio
-
79%
-
Number of buys
-
72
-
Number of sells
-
-60
-
Price
-
$9.88
Significant Holders of HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) as of Q2 2014
166 filings reported holding HALO - HALOZYME THERAPEUTICS, INC. - Common Stock as of Q2 2014.
HALOZYME THERAPEUTICS, INC. - Common Stock (HALO) has 127 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 85,679,010 shares
of 123,650,000 outstanding shares and own 69% of the company stock.
Largest 10 shareholders include Third Security, LLC (19,816,162 shares), IRIDIAN ASSET MANAGEMENT LLC/CT (6,199,685 shares), VANGUARD GROUP INC (6,155,526 shares), BB Biotech AG (5,846,564 shares), QVT Financial LP (4,556,090 shares), Sectoral Asset Management Inc (4,389,682 shares), BlackRock Fund Advisors (3,755,627 shares), FMR LLC (3,207,340 shares), State Street Corp (3,018,348 shares), and BlackRock Institutional Trust Company, N.A. (2,909,476 shares).
This table shows the top 127 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.